RT Journal Article
SR Electronic
T1 Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.05.21251118
DO 10.1101/2021.02.05.21251118
A1 Singh, Prajjval Pratap
A1 Tamang, Rakesh
A1 Shukla, Manoj
A1 Pathak, Abhishek
A1 Srivastava, Anshika
A1 Gupta, Pranav
A1 Bhatt, Alay
A1 Shrivastava, Abhishek K.
A1 Upadhyay, Sudhir K.
A1 Singh, Ashish
A1 Maurya, Sanjeev
A1 Saxena, Purnendu
A1 Singh, Vanya
A1 Chaubey, Akhilesh Kumar
A1 Mishra, Dinesh Kumar
A1 Patel, Yashvant
A1 Pandey, Rudra Kumar
A1 Srivastava, Ankit
A1 Khanam, Nargis
A1 Das, Debashruti
A1 Bandopadhyay, Audditiya
A1 Chorol, Urgyan
A1 Pasupuleti, Nagarjuna
A1 Shrivastav, Sachin Kumar
A1 Prakash, Satya
A1 Mishra, Astha
A1 Dubey, Pavan Kumar
A1 Parihar, Ajit
A1 Basu, Priyoneel
A1 Sequeira, Jaison J
A1 Lavanya, KC
A1 Vijayalaxmi,
A1 Vishnu Shreekara, Bhat. K.
A1 Ijinu, Thadiyan Parambil
A1 Aggarwal, Dau Dayal
A1 Prakash, Anand
A1 Yadav, Kiran
A1 Yadav, Anupam
A1 Upadhyay, Vandana
A1 Mukim, Gunjan
A1 Bhandari, Ankan
A1 Ghosh, Ankita
A1 Kumar, Akash
A1 Yadav, Vijay Kumar
A1 Nigam, Kriti
A1 Harshey, Abhimanyu
A1 Das, Tanurup
A1 Devadas, Deepa
A1 Mishra, Surendra Pratap
A1 Ashish,
A1 Yadav, Abhay Kumar
A1 Singh, Nitish Kumar
A1 Kaur, Manpreet
A1 Kumar, Sanjay
A1 Srivastava, Nikhil
A1 Sharma, Charu
A1 Chowdhury, Ritabrata
A1 Jain, Dharmendra
A1 Kumar, Abhai
A1 Shukla, Ritesh
A1 Mishra, Raghav Kumar
A1 Singh, Royana
A1 Tripathi, Yamini B
A1 Mishra, Vijay Nath
A1 Mustak, Mohammed S.
A1 Rai, Niraj
A1 Rawat, Sumit Kumar
A1 Survajhala, Prashanth
A1 Singh, Keshav K
A1 Mallick, Chandana Basu
A1 Shrivastava, Pankaj
A1 Chaubey, Gyaneshwer
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.05.21251118.abstract
AB Infection born by Coronavirus SARS-CoV-2 has swept the world within a time of a few months. It has created a devastating effect on humanity with social and economic depressions. Europe and America were the hardest hit continents. India has also lost several lives, making the country fourth most deadly worldwide. However, the infection and death rate per million and the case fatality ratio in India were substantially lower than many of the developed nations. Several factors have been proposed including the genetics. One of the important facts is that a large chunk of Indian population is asymptomatic to the SARS-CoV-2 infection. Thus, the real infection in India is much higher than the reported number of cases. Therefore, the majority of people are already immune in the country. To understand the dynamics of real infection as well as level of immunity against SARS-CoV-2, we have performed antibody testing (serosurveillance) in the urban region of fourteen Indian districts encompassing six states. In our survey, the seroprevalence frequency varied between 0.01-0.48, suggesting high variability of viral transmission among states. We also found out that the cases reported by the Government were several fold lower than the real infection. This discrepancy is majorly driven by a higher number of asymptomatic cases. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of the districts, it is less likely to have a second wave in India.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding rceived for this specific work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is approved by the Ethical committe of Banaras Hindu University, Varanasi, IndiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available with the manuscript.